General Information of Drug (ID: DMM5L3S)

Drug Name
VH4004280 Drug Info
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMM5L3S

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lenacapavir DMW7TZV Human immunodeficiency virus-1 infection 1C62 Approved [3]
F4co vaccine DM6UQNW Human immunodeficiency virus infection 1C62 Phase 2 [4]
Vacc-4x DMDAKZW Human immunodeficiency virus-1 infection 1C62 Phase 2 [5]
VH4011499 DM1GSSM Human immunodeficiency virus infection 1C62 Phase 1 [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Capsid p24 (HIV p24) TTTWS2G POL_HV1B1 Inhibitor [2]

References

1 ClinicalTrials.gov (NCT05163522) A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Administered VH4004280 in Healthy Participants. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of ViiV Healthcare
3 Clinical pipeline report, company report or official report of Gilead Sciences.
4 EP patent application no. 2621528, Vaccine.
5 Clinical pipeline report, company report or official report of Bionor Pharma.